interferon for COVID-19: living meta-analysis of clinical studies

Table Graph

interferon - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	1.86 [0.62, 5.58]	< 1	0%	3 studies (3/-)	13.3 %	some concern	not evaluable	moderate	crucial	-
deaths	0.86 [0.53, 1.41]	< 1	20%	9 studies (9/-)	72.3 %	some concern	not evaluable	moderate	crucial	-
deaths (time to event analysis only)	1.74 [0.51, 5.93]	< 1	0%	1 study (1/-)	18.9 %	NA	not evaluable		crucial	-
clinical deterioration	0.50 [0.18, 1.38]	< 1	0%	1 study (1/-)	90.9 %	NA	not evaluable		important	-
clinical improvement	1.39 [0.78, 2.47]	> 1	68%	4 studies (4/-)	87.0 %	some concern	not evaluable	moderate	important	-
clinical improvement (14-day)	1.16 [0.50, 2.72]	> 1	50%	3 studies (3/-)	63.6 %	some concern	not evaluable	moderate	important	-
clinical improvement (28-day)	3.15 [1.39, 7.14]	> 1	0%	1 study (1/-)	99.7 %	NA	not evaluable		important	-
clinical improvement (7-day)	1.91 [1.03, 3.53]	> 1	0%	1 study (1/-)	98.0 %	NA	not evaluable		important	-
clinical improvement (time to event analysis only)	1.66 [0.90, 3.06]	> 1	74%	4 studies (4/-)	94.9 %	some concern	not evaluable	moderate	important	-
death or ventilation	0.83 [0.35, 1.93]	< 1	46%	2 studies (2/-)	67.1 %	some concern	not evaluable	moderate	important	-
hospital discharge	1.97 [0.84, 4.60]	> 1	0%	2 studies (2/-)	94.1 %	some concern	not evaluable	moderate	important	-
hospitalization	1.00 [0.14, 7.34]	< 1	0%	1 study (1/-)	50.0 %	NA	not evaluable		important	-
mechanical ventilation	0.75 [0.34, 1.69]	< 1	0%	3 studies (3/-)	75.5 %	some concern	not evaluable	moderate	important	-
viral clearance	1.61 [0.61, 4.25]	> 1	82%	3 studies (3/-)	83.1 %	some concern	not evaluable	moderate	important	-
viral clearance (time to event analysis only)	0.81 [0.56, 1.18]	> 1	0%	1 study (1/-)	13.7 %	NA	not evaluable		important	-
viral clearance by day 14	0.18 [0.00, 435.69]	> 1	98%	2 studies (2/-)	34.4 %	some concern	not evaluable	moderate	important	-
viral clearance by day 7	2.69 [1.48, 4.87]	> 1	0%	2 studies (2/-)	99.9 %	some concern	not evaluable	moderate	important	-
ICU admission	0.49 [0.24, 1.00]	< 1	0%	3 studies (3/-)	97.4 %	some concern	not evaluable	moderate	non important	-
recovery	2.19 [1.03, 4.67]	> 1	0%	1 study (1/-)	97.9 %	NA	not evaluable		non important	-
safety endpoints 00
serious adverse events	0.99 [0.17, 5.88]	< 1	0%	2 studies (2/-)	50.5 %	some concern	not evaluable	moderate	important	-
superinfection	0.18 [0.02, 1.59]	< 1	0%	1 study (1/-)	93.8 %	NA	not evaluable		important	-
adverse events	1.41 [0.74, 2.67]	< 1	0%	2 studies (2/-)	14.6 %	some concern	not evaluable	moderate	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

interferon - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00